Liso-cel is the third major CD19-specific CAR-T cell product and is awaiting FDA approval based on TRANSCEND-NHL-001 data, a monolithic pivotal project that studied patients with DLBCL NOS, HGBCL (double-hit lymphoma), transformed indolent B-cell lymphomas, follicular lymphoma grade 3B, and PMBCL (163). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.